NCT01878617 2025-11-13
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT01601184 2019-05-21
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Centre Leon Berard
Phase 1/2 Terminated
NCT01239316 2016-01-14
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00822458 2014-04-02
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
National Cancer Institute (NCI)
Phase 1 Completed